A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge
Basic & Clinical Pharmacology & Toxicology · 2024
DOI: 10.1111/bcpt.14050 ↗At a glance
Journal article in Basic & Clinical Pharmacology & Toxicology, 2024. Written by Louise Westberg Strejby Christensen and 7 co-authors. Institution: Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark. Major MEDLINE topics: Receptors, Urokinase Plasminogen Activator, Patient Discharge, Biomarkers, Registries. Cited 2 times so far (Crossref); 39 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Capital Regions Fund for Transitional Research, Danish Research Unit for Hospital Pharmacy, Amgros I/S, Copenhagen, Denmark, The Lundbeck Foundation.
Abstract (original language)
Soluble urokinase plasminogen activator receptor (suPAR) is a marker of systemic chronic inflammation. Elevated suPAR levels are associated with adverse clinical outcomes, but a small subset of patients with low suPAR also experience poor outcomes. Therefore, we aimed to characterize patients presenting to the emergency department with low suPAR (
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Clinical Research, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
- The Capital Region Pharmacy, Herlev, Denmark.
- Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Psychology and Neuroscience, Duke University, Durham, North Carolina, USA.
- Emergency Department, Copenhagen University Hospital Amager and Hvidovre, Hvidovre, Denmark.
ORCID profiles: Louise Westberg Strejby Christensen, Esben Iversen, Morten Baltzer Houlind
Funding
- Capital Regions Fund for Transitional Research
- Danish Research Unit for Hospital Pharmacy, Amgros I/S, Copenhagen, Denmark
- The Lundbeck Foundation
- Novo Nordisk Foundation
- BRIDGE-Translational Excellence Program
- Lundbeck Foundation
- Novo Nordisk Fonden
Cite
APA
Christensen, L. W. S., Iversen, E., Andersen, A. L., Walls, A. B., Rasmussen, L. J. H., Andersen, O., Kallemose, T., & Houlind, M. B. (2024). A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.14050
Vancouver
Christensen LWS, Iversen E, Andersen AL, Walls AB, Rasmussen LJH, Andersen O, et al. A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge. Basic & Clinical Pharmacology & Toxicology. 2024. doi:10.1111/bcpt.14050
BibTeX
@article{Christensen2024,
author = {Christensen, Louise Westberg Strejby and Iversen, Esben and Andersen, Aino Leegaard and Walls, Anne Byriel and Rasmussen, Line Jee Hartmann and Andersen, Ove and Kallemose, Thomas and Houlind, Morten Baltzer},
title = {A characterization of patients with low soluble urokinase plasminogen activator receptor who died within 90 days of hospital discharge},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2024},
doi = {10.1111/bcpt.14050}
}
EUVIMED